CureGLIO | Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.

Summary
Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to treat GBM and all of them provide marginal improvements of
Resources
Show all and search (1)
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/190184696
Start date: 01-01-2023
End date: 31-12-2025
Total budget - Public funding: 21 516 125,00 Euro - 2 500 000,00 Euro
Cordis data

Original description

Glioblastoma Multiform (GBM) patients usually die 12-18 months after diagnosis, with a 5-year survival rate of 6.8%. There are only 5 therapies approved to treat GBM and all of them provide marginal improvements of

Status

SIGNED

Call topic

HORIZON-EIC-2022-ACCELERATOROPEN-01

Update Date

31-07-2023
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
EU-Programme-Call
Horizon Europe
HORIZON.3 Innovative Europe
HORIZON.3.1 The European Innovation Council (EIC)
HORIZON.3.1.0 Cross-cutting call topics
HORIZON-EIC-2022-ACCELERATOR-01
HORIZON-EIC-2022-ACCELERATOROPEN-01 EIC Accelerator Open
Search
Search on Google
Search on Bing
Search on DuckDuckGo
Organisations
Show all (1)
Powered by Chris Decubber BV